Tuesday, 19 Jun 2018

You are here

IV Golimumab in Psoriatic Arthritis

Simponi (golimumab) is approved by the FDA for use in rheumatoid arthritis, psoriatic arthritis (PsA), anklylosing spondylitis (AS) and ulcerative colitis. The intravenous (IV) formulation of golimumab (GOL) is approved for RA only.

Based on recent clinical trials, the makers of GOL have petitioned the FDA for new indications in PsA and AS. Trials for PsA (GO-VIBRANT) and AS (GO-ALIVE) were presented at last weeks EULAR 2017 meeting in Madrid, Spain.

The GO-VIBRANT trial results of IV GOL in PsA garnered enthusiastic reviews from KOLs and those in attendance. 

This phase 3 study was a multicenter, double-blind, placebo-controlled trial, of IV GOL in biologic-naïve adult PsA patients. They enrolled 480 patients to receive either placebo or Simponi Aria 2mg/kg at Weeks 0, 4, and every 8 weeks for 24 weeks. The primary endpoint was the ACR20 response at Week 14.

At Week 14, the ACR 20 responses were 75.1% GOL vs. 21.8% PBO. Similar, impressive ACR50 and ACR70 responses were seen at week 14. (43.6% and 24.5%, respectively). At week 24 the ACR 50 responses were superior to PBO (53.5% vs. 6.3%). Significant responses in enthesitis, dactylitis and skin were seen. The PASI75 responses were superior to PBO (59.2% vs. 13.6%).

At week 24 there was also significant inhibition of joint destruction and damage, joint erosion, and joint space narrowing compared to placebo.

There were 2 deaths, 2 malignancies, and 1 demyelinating event; no opportunistic infections or tuberculosis noted.

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Increased Risk of Infection in Psoriasis and Psoriatic Arthritis

As we gather more knowledge about psoriatic arthritis ( PsA) and psoriasis (PSO) over time, and achieve better outcomes with new therapies, more questions arise about quality of life, survival  and comorbidities in PsA and PSO. Similarly to RA, we learned about increased risk of CVD and malignancy. With more data compiled in cohorts it is possible now to ask the same questions as we asked in RA.

Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA

Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides. A single center cross -sectional observational study was designed to conduct deeper analysis of Cardiovascular Risk Factors (CVRF) in patients with PsA, PSO without arthritis and SpA without PSO (THU 0297).

MRI Imaging for Sacroiliitis Requires Bone Marrow Edema for Reliability

de Winter and colleagues from the Netherlands have reported on magnetic resonance imaging of the sacroiliac joints of healthy subjects, patients with axial spondyloarthritis, runners and those with chronic back pain, and found a high incidence of sacroiliitis in many, but that deep bone marrow edema was most specific for those with axial SpA.

Cancer Risk Raised in Psoriatic Arthritis

Patients with psoriatic arthritis (PsA) were at increased risks for malignancy, and possibly more so if they were treated with conventional disease-modifying antirheumatic drugs (DMARDs), a meta-analysis found.

In nine cohort studies that included more than 43,000 PsA patients, the pooled relative risk for overall malignancy was 1.29 (95% CI 1.04-1.60) compared with the general population, according to Yunyun Fei, MD, and colleagues from Peking Union Medical College in Beijing.

Trends in Psoriatic Arthritis Treatment 2004-2015

Lee and colleagues from Brigham and Women's Hospital have analyzed the last decade of disease‐modifying antirheumatic drugs (DMARDs) use in patients with psoriatic arthritis (PsA) and found nearly 40% were treated with a bDMARD, along with a decreasing trend in complete DMARD discontinuations.